Showing results (411-420 of 446) with videos related to

Sort By:
Pageof 45
Advances in Radiation Oncology|April 11, 2025
Self-Reported Health Status Survey Creation and Distribution Outcomes in a Large Cohort of Pediatric Oncology Patients Treated with Proton Radiation TherapyMiranda P Lawell, Melanie L Rose, Jaitri Joshi, et al.
European Journal of Human Genetics : EJHG|May 15, 2014
6q22.1 microdeletion and susceptibility to pediatric epilepsyPrzemyslaw Szafranski, Gretchen K Von Allmen, Brett H Graham, et al.
Ebiomedicine|May 6, 2018
Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating AgentsMatthieu Duchmann, Fevzi F Yalniz, Alessandro Sanna, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|March 25, 2020
CSACI guidelines for the ethical, evidence-based and patient-oriented clinical practice of oral immunotherapy in IgE-mediated food allergyP Bégin, E S Chan, H Kim, et al.
Blood|June 11, 2024
Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trialLindsey E Roeker, Jennifer A Woyach, Chan Y Cheah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2019
Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced MalignanciesGerald Falchook, Seth Rosen, Patricia LoRusso, et al.
Science Translational Medicine|June 21, 2023
High-resolution daily profiles of tissue adrenal steroids by portable automated collectionThomas J Upton, Eder Zavala, Paal Methlie, et al.
Acta Haematologica|June 2, 2024
Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell MalignanciesLindsey E Roeker, Catherine C Coombs, Nirav N Shah, et al.
Leukemia|January 5, 2020
Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDSJoshua F Zeidner, Hanna A Knaus, Amer M Zeidan, et al.
Current Medical Research and Opinion|January 30, 2026
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysisCatherine C Coombs, Jennifer A Woyach, Jennifer R Brown, et al.
Pageof 45